Recalibrated and extended UK FRAX for 10-year risk of hip fracture (CPRD-HES) in RA
| β-coefficient | OR (95% CI) | Shrunken β-coefficient* | |
|---|---|---|---|
| Recalibrated UK FRAX | |||
| Intercept | −1.085 | – | −1.080 |
| UK FRAX† | 0.757 | 2.13 (1.92 to 2.37) | 0.749 |
| Extended UK FRAX | |||
| Intercept | −0.728 | – | −0.713 |
| UK FRAX† | 0.939 | 2.56 (2.17 to 3.02) | 0.921 |
| Secondary osteoporosis (yes/no) | 0.521 | 1.68 (1.04 to 2.74) | 0.511 |
| Glucocorticoid >7.5 mg/day (yes/no) | −1.303 | 0.27 (0.09 to 0.87) | −1.276 |
| Duration of RA disease (per year increase) | −0.029 | 0.97 (0.95 to 0.99) | −0.029 |
| Duration of RA disease† UK FRAX† | −0.015 | 0.99 (0.98 to 0.99) | −0.015 |
*The shrunken β-coefficients were derived by applying the shrinkage factor (0.98 for the extended model and 0.99 for the recalibrated model) to the original β-coefficients.
†Log odds transformed 10-year risks of hip fracture (ln(probhip/(1 − probhip)) as derived from the original UK FRAX algorithm.
CPRD, Clinical Practice Research Datalink; HES, Hospital Episode Statistics; RA, rheumatoid arthritis.